Category: ASX-NYR

Nyrada Inc. (ASX:NYR) reports significant cardioprotective findings for NYR-BI03 in preclinical studies, demonstrating potential for treating heart attack-related conditions.

Nyrada Inc. (ASX:NYR) advances its Phase I clinical trial to the second cohort, anticipating final readouts in Q3 CY2025.